Dive into the latest updates and breakthroughs from clinical trials targeting Non-Alcoholic Steatohepatitis (NASH). Understand how these trials are shaping the future of NASH treatment
Explore Prof. Wong's insights on MASLD treatment advancements from AASLD, featuring key drugs like Resmetirom, Lanifibranor, and Semaglutide with a focus on Lanifibranor
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in recent years due to its direct link with obesity and type 2 diabetes (T2D).
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.